NS-304 PAH

The clinical study to assess the efficacy, safety and pharmacokinetics of NS-304 in patients with pulmonary arterial hypertension (PAH)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221493

Enrollment

Registered

2011-06-27

Start date

2011-06-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension (PAH)

Interventions

investigational material(s) Generic name etc : NS-304 INN of investigational material : Selexipag Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Idiopathic pulmonary arterial hypertension (IPAH) Heritable pulmonary arterial hypertension (HPAH) Drug- and Toxin-induced pulmonary arterial hypertension PAH associated with one of the following; a) connective tissue disease b) congenital heart disease (At least one year should be elapsed after pulmonary shunt at the time of each baseline measurement.) c) HIV infection

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change from baseline of pulmonary vascular resistance (PVR)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026